Keith Paull, MD
Allergy/ Immunology · College Station, TXNPI 1992798532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,949, 2.5 times the $1,188 reported in 2019.
Across 267 payments — averaging $40.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$1K
- GSK$826
- Pfizer$601
- Optinose US, Inc.$594
- AbbVie$574
- plus $6K from 32 others
Across 15 payments — averaging $2129.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$32K
What the payments were for
- Food & beverage$10,898100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $1,226 |
| Sanofi | 24 | $1,217 |
| GSK | 12 | $826 |
| Pfizer | 17 | $601 |
| Optinose US, Inc. | 20 | $594 |
| AbbVie | 18 | $574 |
| Regeneron Healthcare Solutions, Inc. | 20 | $565 |
| Grifols USA, LLC | 3 | $434 |
| Novartis | 12 | $434 |
| Incyte Corporation | 8 | $398 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $391 |
| Lilly USA, LLC | 10 | $350 |
| Genentech USA, Inc. | 6 | $345 |
| Pharming Healthcare, Inc. | 8 | $321 |
| Blueprint Medicines Corporation | 9 | $296 |
| Genentech, Inc. | 2 | $267 |
| Teva Pharmaceuticals USA, Inc. | 3 | $248 |
| Boehringer Ingelheim | 2 | $246 |
| Organon | 2 | $230 |
| Octapharma USA, Inc. | 3 | $165 |
| Galderma Laboratories, L.p. | 2 | $144 |
| Biohaven Pharmaceuticals, Inc. | 1 | $124 |
| Biocryst US Sales Co., LLC | 1 | $124 |
| Amgen | 6 | $123 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $122 |
| Shire North American Group Inc | 1 | $108 |
| Cycle Pharmaceuticals Inc | 1 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Kaleo, Inc. | 4 | $68 |
| Johnson & Johnson | 3 | $48 |
| CSL Behring | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 2 | $33 |
| Merck | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Hospira, Inc. | 1 | $18 |
| LEO Pharma Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 2 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,074
- XOLAIR$502
- Xembify$434
- Xhance$355
- OPZELURA$242
- AIRSUPRA$236
- TEZSPIRE$234
- Rinvoq$232
- NUCALA$231
- VTAMA$230
- NEMLUVIO$132
- CIBINQO$126
- ArmonAir Digihaler$125
- ProAir Digihaler$125
- AirDuo RespiClick$125
- NURTEC ODT$124
- Orladeyo$124
- RUCONEST$116
- CINQAIR$115
- AYVAKIT$111
How this compares
Too few allergy/ immunology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 36 | $200,040 |
| Dupixent PenDupilumab | 16 | $156,719 |
| RexultiBrexpiprazole | 12 | $19,388 |
| Dexlansoprazole DrDexlansoprazole | 77 | $15,522 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $14,247 |
| Esomeprazole Magnesium | 425 | $11,583 |
| XhanceFluticasone Propionate | 16 | $11,124 |
| XiidraLifitegrast | 13 | $10,918 |
| Epinephrine | 40 | $8,233 |
| Cyclosporine | 13 | $5,432 |
| Fluticasone Propionate | 294 | $4,623 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 23 | $4,451 |
| Amitriptyline Hcl | 280 | $3,089 |
| Cyclosporine ModifiedCyclosporine, Modified | 30 | $2,815 |
| MethotrexateMethotrexate Sodium | 92 | $2,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $267 | $200,04036 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $72 | $19,38812 claims |
| GSKBreo Ellipta | $826 | $14,24723 claims |
| Optinose US, Inc.Xhance | $594 | $11,12416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Texason file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in College Station
- William LumryDallas$1.3M
- Priyanka GuptaNew Braunfels$207K
- Dalys GomezSan Antonio$6K
- Jamie YeagerDallas$5K
- John van WagonerPlano$5K
- Pramila DaftaryWaco$3K
- Luis GonzalezEl Paso$2K
- Robert LekachBrownsville$310
- John YorkEl Paso$0
- John MastrovichSan Antonio$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.